Keywords
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
References
Altshuler HL Phillips PA, Feinhandler DA (1980) Alternation of enthanol self-administration by naltrexone. Life Sciences 26: 679–688
Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Archives of General Psychiatry 49: 876–880
Volpicelli JR, O’Brien CP, Alerman AI, Hayashida M (1990) Naltrexone and the treatment of alcohol dependence: initial observations. In: LB Reid (ed.): Opioids, Bulimia, Alcohol Abuse and Alcoholism, Springer-Verlag, New York, 195–214
O’Malley SS, Jaffe, AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence: a control study. Arch Gen Psychiat 49: 881–887
Harris KM, DeVries A, Dimidjian K (2004) Datapoints: Trends in naltrexone use among members of a large private health plan. Psychiatric Services 55(3): 221
Kranzler HR, Modesto-Lowe V, Van Kirk J (2000) Naltrexone versus nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology 22(5): 493–503
Krystal JH, Cramer JA, Krol WF, Kirk GF, Rosenheck RA, Veterans Affairs Naltrexone Cooperative Study 425 Group (2001) Naltrexone in the treatment of alcohol dependence. N Engl J Med 345(24): 1734–1739
Gastpar M, Bonnet U, Boning J. Mann K. Schmidt LG. Soyka M. Wetterling T. Kielstein V. Labriola D. Croop R (2002) Lack of efficacy of naltrexone in the prevention of alcohol relapse: results from a German multicenter study. J Clin Psychopharmacol 22(6): 592–598
Pettinanti HM, Oslin D, O’Brien CP (in preparation) A review of all naltrexone clinical trials for alcoholism
Robinson DS, Rickels K (2000) Concerns about clinical drug trials. Journal of Clinical Psychopharmacology 20(6): 593–596
Chan A-W, Hrobjartsson A, Haahr M, Gotzsche PC, Altman DG (2004) Empirical evidence for selective reporting of outcomes in randomized trials. JAMA 291(20): 2457–2465
Thase M (2003) Issues and Ethics. Presented at the Annual American College of Neuropsychopharmacology Annual Meeting, San Juan, Puerto Rico
Koob GF, Rassnick S, Heinrichs S, Weiss F (1994) Alcohol, the reward system and dependence. Exs 71: 103–114
Gonzales RA, Weiss F (1998) Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. The Journal of Neuroscience 18(24): 10663–10671
Gianoulakis C (1996) Implications of endogenous opioids and dopamine in alcoholism: human and basic science studies. Alcohol and Alcoholism 31(1): 33–42
Genazzani AR, Nappi G, Facchinetti F, Mazzella GL, Parrini D, Sinforiani E, Petraglia F, Savoldi F (1982) Central deficiency of beta-endorphin in alcohol addicts. J Clin Endocrinol Metab 55(3): 583–586
Gianoulakis C (1990) Characterization of the effects of acute ethanol administration on the release of beta-endorphin peptides by the rat hypothalamus. Eur J Pharmacol 180: 21–29
King A, Volpicelli J, Frazer A, O’Brien CP (1997) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129: 15–22
Volpicelli JR, Clay KL, Watson NT, O’Brien CP (1995) Naltrexone in the treatment of alcoholism: predicting response to naltrexone. Journal of Clinical Psychiatry 56: 39–44
Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. American Journal of Psychiatry151(10): 1463–1467
Davidson D, Palfai T, Bird C, Swift R (1999) Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23(2): 195–203
Volpicelli JR, Rhines KC, Rhines, JS, Volpicelli LA, Alterman, AI, O’Brien CP (1997) Naltrexone and alcohol dependence. Role of subject compliance. Arch Gen Psychiatry 54(8): 737–742
Chick J., Anton R, Checinski K. Croop R. Drummond DC. Farmer R. Labriola D. Marshall J Moncrieff J. Morgan MY. Peters T. Ritson B. (2000) A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol and Alcoholism 35(6): 587–593
O’Malley SS, Krishnan-Sarin S, Farren C, O’Connor PG (2000) Naltrexone-induced nausea patients treated for alcohol dependence: clinical predictors and evidence for opioid-mediated effects. J Clin Psychopharmacol 20(1): 69–76
Wand GS, Mangold, D, El Deiry S, McCaul ME, Hoover D (1998) Family history of alcoholism and hypothalamic opioidergic activity. Arch Gen Psychiatry 55(12): 1114–1119
Kranzler HR, Modesto V, Nuwayser ES (1998) A sustained-release naltrexone preparation for treatment of alcohol dependence. Alcoholism: Clinical and Experimental Research 22(5): 1074–1079
Kranzler HR, Wesson DR, Billot L for the Drug Abuse Sciences Naltrexone Depot Study Group (2004) Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcoholism: Clinical and Experiment Research 28(7): 1051–1059
Silverman B (2004) Clinical Trial of Depot Naltrexone. Presented at the American Psychiatry Association Annual Meeting, New York City, New York
Schmidt WK, Tam SW, Shotzberger GS, Smith DH Jr, Clark R, Vernier VG (1985) Nalbuphine. Drug Alcohol Depend 14(3–4): 339–362
Stromberg MF, Casale M, Volpicelli L, Volpicelli JR, O’Brien CP (1998) A comparison of the effects of the opioid antagonists naltrexone, naltrindole, and beta-funaltrexamine on ethanol consumption in the rat. Alcohol 15(4): 281–289
Lee MC, Wagner HN, Tanada S, Frost JJ, Bice AN, Dannals RF (1988) Duration of occupancy of opiate receptors by naltrexone. J Nuclear Med 29(7): 1207–1211
McCaul ME, Kim WK Wand GS, Bencherif B, Dannals RF, Frost JJ (2004) PET Measurement of μ-and d-opioid receptor availability before and during naltrexone treatment in alcohol dependent subjects (poster). Presented at the Winter Conference on Brain Research, Copper Mountain, Colorado
Tiffany ST (1999) Cognitive concepts of craving. Alcohol Res Health 23(3): 215–224
Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, Gulliver SB, Gordon A, Abrams DB (1999) Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23(8): 1386–1394
O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol dependent subjects and activates the hypothalamopituitary-adrenocortical axis. Psychopharmacology 160(1): 19–29
Latt NC, Jurd S, Houseman J, Wutzke SE (2002) Naltrexone in alcohol dependence: a randomized controlled trial of effectiveness in a standard clinical setting. The Medical Journal of Australia 176(11): 530–534
Pettinati HM, Volpicelli JR, Pierce JD, O’Brien CP, Pierce JD Jr, (2000) Improving naltrexone response: an intervention for medical practitioners to enhance medication compliance in alcohol dependent patients. J Addict Dis 19(1): 71–83
Jaffe AJ, Rounsaville B, Chang G, Schottenfeld RS, Meyer RE, O’Malley SS (1996) Naltrexone, relapse prevention, and supportive therapy with alcoholics: an analysis of patient treatment matching. J Consult Clin Psychol 64(5): 1044–1053
Monterosso JR, Flannery BA, Pettinati HM, Oslin DW, Rukstalis M, O’Brien CP, Volpicelli JR (2001) Predicting treatment response to naltrexone: the influence of craving and family history. Am J Addict 10(3): 258–268
Oslin DW, Berrettini W, Kranzler HR, Pettinati H, Gelernter J, Volpicelli JR, O’Brien CP (2003) A functional polymorphism of the μ-opioid receptor gene is associated with naltrexone response in alcohol-dependent patients. Neuropsychopharmacology 28: 1546–1552
Wand GS, Mangold E, El Deiry S, McCaul ME, Hoover D (1998) Family history of alcoholism and hypothalamic opioidergic activity. Arch Gen Psychiatry 55: 1114–1119
Hernandez-Avila C, Wand G, Luo X, Gelernter J, Kranzler H (2003) Association between the cortisol response to opioid blockade and the Asn40Asp polymorphism at the mu-opioid receptor locus (OPRM1). Am J Med Genet 118B: 60–65
Smolka M. Sander T, Schmidt L, Samochowiec J, Rommelspacher H, Gschiedel N, Wendel B. Hoehe MR (1999) Mu-opioid receptor variants and dopaminergic sensitivity in alcohol withdrawal. Psychoneuroendocrinology 24: 629–638
Kim SG, Kim C-M, Kang D-H, Kim J-K, Byun W-T, Kim S-Y, Park J-M, Kim M-J, Oslin DW (2004) Association of functional opioid receptor genotypes with alcohol dependence in Koreans. Alcohol Clin Exp Res 28(7): 986–990.
McLellan AT, Luborsky L, Woody GE, O’Brien CP (1980) An improved diagnostic evaluation instrument for substance abuse patients: The Addiction severity Index. J Nervous and Mental Disease 168: 26–33
Kiefer F, Jahn H, Tarnaske T, Helwig H, Briken P, Holzbach R, Kampf P, Stracke R, Baehr M, Naber D, Widemann K (2003) Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch Gen Psychiatry 60(1): 92–99
Lesch, OM (2004) How to translate the biological basic glutamate mechanisms in preclinical research to human trials and therapy approaches. Presented at the European Winter Conference on Brain Research, Les Arcs, France
Oslin DW, Pettinati H, Volpicelli JR (2002) Alcoholism treatment adherence: older age predicts better adherence and drinking outcomes. Am J Geriatr Psychiatry 19(6); 740–747
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2005 Birkhäuser Verlag/Switzerland
About this chapter
Cite this chapter
O’Brien, C.P., Pettinati, H.M., Oslin, D.W. (2005). Naltrexone: clinical data. In: Spanagel, R., Mann, K.F. (eds) Drugs for Relapse Prevention of Alcoholism. Milestones in Drug Therapy MDT. Birkhäuser Basel. https://doi.org/10.1007/3-7643-7305-9_6
Download citation
DOI: https://doi.org/10.1007/3-7643-7305-9_6
Publisher Name: Birkhäuser Basel
Print ISBN: 978-3-7643-0214-6
Online ISBN: 978-3-7643-7305-4
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)